Literature DB >> 16087247

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

Mathula Thangarajh1, Thomas Masterman, Uros Rot, Kristina Duvefelt, Boel Brynedal, Virginija Danylaité Karrenbauer, Jan Hillert.   

Abstract

B cells play an indispensable, yet indeterminate, role in the pathogenesis of multiple sclerosis (MS). We measured mRNA of APRIL-a promotor of B-cell survival-in peripheral blood and quantified protein levels in plasma and cerebrospinal fluid in MS patients and controls. APRIL mRNA levels in monocytes and T cells were significantly higher in MS patients than in controls. Levels of soluble APRIL in plasma were higher in patients with chronic progressive MS than in patients with relapsing-remitting MS, albeit not significantly. MS may thus be associated with increased transcription in peripheral blood of factors promoting B-cell survival, including APRIL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087247     DOI: 10.1016/j.jneuroim.2005.06.024

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  10 in total

1.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Atacicept: targeting B cells in multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2010-07       Impact factor: 6.570

Review 3.  Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.

Authors:  Henrik Gensicke; David Leppert; Özgür Yaldizli; Raija L P Lindberg; Matthias Mehling; Ludwig Kappos; Jens Kuhle
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 4.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

5.  CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation.

Authors:  Markus C Kowarik; Sabine Cepok; Johann Sellner; Verena Grummel; Martin S Weber; Thomas Korn; Achim Berthele; Bernhard Hemmer
Journal:  J Neuroinflammation       Date:  2012-05-16       Impact factor: 8.322

6.  Serum BAFF and APRIL levels in patients with IgG4-related disease and their clinical significance.

Authors:  Kazuhiro Kiyama; Daisuke Kawabata; Yuji Hosono; Koji Kitagori; Naoichiro Yukawa; Hajime Yoshifuji; Koichiro Omura; Takao Fujii; Tsuneyo Mimori
Journal:  Arthritis Res Ther       Date:  2012-04-24       Impact factor: 5.156

7.  Identification of TNFSF13, SPATC1L, SLC22A25 and SALL4 as novel susceptibility loci for atrial fibrillation by an exome‑wide association study.

Authors:  Yoshiji Yamada; Jun Sakuma; Ichiro Takeuchi; Yoshiki Yasukochi; Kimihiko Kato; Mitsutoshi Oguri; Tetsuo Fujimaki; Hideki Horibe; Masaaki Muramatsu; Motoji Sawabe; Yoshinori Fujiwara; Yu Taniguchi; Shuichi Obuchi; Hisashi Kawai; Shoji Shinkai; Seijiro Mori; Tomio Arai; Masashi Tanaka
Journal:  Mol Med Rep       Date:  2017-08-23       Impact factor: 2.952

Review 8.  What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?

Authors:  Katherine A Buzzard; Simon A Broadley; Helmut Butzkueven
Journal:  Int J Mol Sci       Date:  2012-10-04       Impact factor: 5.923

9.  APRIL, a proliferation-inducing ligand, as a potential marker of lupus nephritis.

Authors:  Worapot Treamtrakanpon; Pornpen Tantivitayakul; Thitima Benjachat; Poorichaya Somparn; Wipawee Kittikowit; Somchai Eiam-ong; Asada Leelahavanichkul; Nattiya Hirankarn; Yingyos Avihingsanon
Journal:  Arthritis Res Ther       Date:  2012-11-21       Impact factor: 5.156

10.  Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms.

Authors:  Annie George-Chandy; Estelle Trysberg; Kristina Eriksson
Journal:  Arthritis Res Ther       Date:  2008-08-22       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.